Sharon Bio-Medicine declines on profit taking

Image
Capital Market
Last Updated : Jun 24 2016 | 3:29 PM IST

Sharon Bio-Medicine lost 5.59% to Rs 12 at 14:39 IST on BSE, with the stock sliding on profit booking after recent rally triggered by the company's announcement with regard to its business expansion plans.

Meanwhile, the S&P BSE Sensex was down 664.53 points or 2.46% at 26,337.69.

On BSE, so far 2.78 lakh shares were traded in the counter as against average daily volume of 1.47 lakh shares in the past one quarter. The stock hit a high of Rs 12.80 and a low of Rs 11.05 so far during the day. The stock had hit a 52-week low of Rs 8.40 on 2 June 2016. The stock had hit a 52-week high of Rs 32.55 on 16 December 2015. The stock had outperformed the market over the past one month till 23 June 2016, advancing 13.99% compared with Sensex's 7.02% rise. The scrip had also outperformed the market in past one quarter, gaining 8.17% as against Sensex's 6.57% rise.

The small-cap company has equity capital of Rs 23.79 crore. Face value per share is Rs 2.

Shares of Sharon Bio-Medicine had rallied 31.16% in two trading sessions to settle at Rs 12.71 yesterday, 23 June 2016, from its close of Rs 9.69 on 21 June 2016, after the company after market hours on 21 June 2016, announced that its board has decided to introduce more profitable products and increase capacity utilization. Sharon Bio-Medicine's board of directors at its meeting held on 21 June 2016, discussed the current financial position of the company and decided to introduce more profitable products, increase capacity utilization and get the business to move in the regulated markets specifically the United States of America.

On consolidated basis, Sharon Bio-Medicine reported net loss of Rs 153.73 crore in Q3 March 2016, higher than net loss of Rs 56.43 crore in Q3 March 2015. Net sales declined 72.6% to Rs 35.77 crore in Q3 March 2016 over Q3 March 2015.

Sharon Bio-Medicine is engaged in manufacture of intermediates, active pharmaceutical ingredients (API) and finished dosage forms

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 24 2016 | 2:35 PM IST

Next Story